Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a type of lung disease that causes scarring (fibrosis) of the lungs for no known reason. Over time, the scars worsen, it becomes difficult to take a deep breath, and the lungs cannot absorb enough oxygen.
IPF is a form of interstitial lung disease that primarily affects interstitial tissue (the tissue and space around the air sacs of the lungs) and does not directly affect the airways or blood vessels. There are many other types of interstitial lung disease that can also cause inflammation and / or fibrosis and are treated in different ways. It is important to check with your doctor to determine if you have IPF or another form of interstitial lung disease.
Related Conference of Idiopathic Pulmonary Fibrosis
October 24-25, 2024
4th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
Paris, France
Idiopathic Pulmonary Fibrosis Conference Speakers
Recommended Sessions
- Airway and Therapeutic Devices
- Asthma and Allergy
- Cardiopulmonary Disorders
- Case Reports in Pulmonology
- Chronic Bronchitis and Respiratory Diseases
- Chronic Obstructive Pulmonary Disease
- Cystic Fibrosis
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Lung Diseases
- Obstructive sleep apnea
- Pediatric Pulmonology and Critical care
- Pulmonary Diseases and therapeutics
- Pulmonary Hypertension
- Pulmonary Rehabilitation
- Respiratory tract Infections
- Sarcoidosis
- Thoracic
- Tuberculosis
Related Journals
Are you interested in
- Advancements in Pulmonary Diagnostics - Respiratory 2024 (France)
- Asthma - Tuberculosis-2024 (France)
- Atelectasis and Pneumothorax - Tuberculosis-2024 (France)
- Cardio Pulmonary Disorders - Respiratory 2024 (France)
- Cardiopulmonary Disease - Tuberculosis-2024 (France)
- Chronic Obstructive Pulmonary Disease - Respiratory 2024 (France)
- Chronic Obstructive Pulmonary Disease (COPD) - Tuberculosis-2024 (France)
- Climate Change and Respiratory Diseases - Tuberculosis-2024 (France)
- COVID-19 and Asthma - Respiratory 2024 (France)
- COVID-19 and Respiratory System - Respiratory 2024 (France)
- Epidemiology of TB Disease - Tuberculosis-2024 (France)
- Gastroesophageal reflux disease (GERD) - Tuberculosis-2024 (France)
- Idiopathic Pulmonary Fibrosis - Respiratory 2024 (France)
- Interstitial Lung Disease - Respiratory 2024 (France)
- Latent TB Infection and Active TB Disease - Tuberculosis-2024 (France)
- Lung Cancer - Respiratory 2024 (France)
- Lung Cancer: Screening, Diagnosis & Treatment - Tuberculosis-2024 (France)
- Lung Function in Men with and without HIV - Tuberculosis-2024 (France)
- Lung Infection - Tuberculosis-2024 (France)
- Lung Transplantation - Respiratory 2024 (France)
- Multidrug-resistant TB - Tuberculosis-2024 (France)
- Mycobacterial Infections - Tuberculosis-2024 (France)
- Obstructive Sleep Apnea - Respiratory 2024 (France)
- Occupational Lung Diseases - Respiratory 2024 (France)
- Palliative Care for Advanced Lung Cancer - Tuberculosis-2024 (France)
- Pneumonia - Respiratory 2024 (France)
- Pulmonary Complications of Endocrine Diseases - Tuberculosis-2024 (France)
- Pulmonary Diseases and Therapeutics - Tuberculosis-2024 (France)
- Pulmonary diseases: Treatment, Diagnosis and therapies - Respiratory 2024 (France)
- Pulmonary Edema - Tuberculosis-2024 (France)
- Pulmonary Hypertension - Respiratory 2024 (France)
- Pulmonary Rehabilitation - Respiratory 2024 (France)
- TB Clinical Trials - Tuberculosis-2024 (France)
- TB Diagnosis, Prevention & Treatment - Tuberculosis-2024 (France)
- TB Vaccines - Tuberculosis-2024 (France)
- TB-HIV Co-infections - Tuberculosis-2024 (France)
- Tuberculosis - Respiratory 2024 (France)
- Zoonotic TB - Tuberculosis-2024 (France)